沙利度胺联合三氧化二砷和维甲酸治疗低危骨髓增生异常综合征  

Use of Thalidomide with Arsenious Oxide and Retinoic Acid in Low Risk Myelodysplastic Syndromes

作　　者：万纯黔[1] 王晓冬[1] 张晋林[1] 王春森[1] 甘茂周[1] 祝彪[1] 

机构地区：[1]四川省人民医院血液科,四川成都610072

出　　处：《华西医学》2008年第5期1044-1045,共2页West China Medical Journal

摘　　要：目的:观察沙利度胺联合三氧化二砷和维甲酸治疗低危骨髓增生异常综合征(MDS)的疗效和不良反应。方法:49例低危MDS患者均为难治性贫血(RA),分为两组,A组使用三氧化二砷和维甲酸,B组除该两种药物外还联合使用沙利度胺。比较两组的疗效,观察沙利度胺的副反应。结果:A组总有效率为39.1%,缓解率为26.1%;B组总有效率为75.0%,缓解率为54.2%,两者均为显著差异(P<0.05)。A组血红蛋白(Hb)增加大于30 g/L的平均时间为135.9±23.7天,B组为93.8±33.5天,差异非常显著(P<0.005)。A组平均红细胞输注量为18.1±8.0单位,B组为10.6±7.0单位,差异也有显著性(P<0.005)。沙利度胺的主要不良反应是嗜睡、便秘和水肿。结论:沙利度胺联合三氧化二砷和维甲酸治疗低危MDS优于仅用三氧化二砷和维甲酸,且毒副作用小,值得临床推广使用。Objective:To observe the therapeutic effects and side-effects of thalidomide combined with arsenious oxide and retinoic acid for the treatment of low-risk myelodysplastic syndromes(MDS).Methods:A total of 49 patients with low-risk MDS were enrolled who suffered from refractory anemica(RA).They were divided into two groups.The patients in group A were treated with arsenious oxide and retinoic acid,patients of group B were treated with arsenious oxide,retinoic acid and thalidomide.The effects of two groups we...

关 键 词：骨髓增生异常综合征 低危 沙利度胺 

分 类 号：R551.3[医药卫生—血液循环系统疾病]